Get the app
US › Healthcare

MacroGenics Inc (MGNX)

US · Healthcare · Biotechnology

$2.33+4.95%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$32.8M
Revenue YoY
+47.6%
Net profit
$19.5M
EPS
$-0.27
EPS estimate
$-0.34
Net margin
59.4%

EPS came in at -0.27 against a street estimate of -0.34 — a beat of 20.6%.

Key statistics

Market cap
$141.4M
Forward P/E
61.0
P/B
3.43
Book value
$0.67
EPS (TTM)
$-1.63
52-week high
$5.08
52-week low
$1.32
50-day MA
$3.58
200-day MA
$3.43
Beta
1.32

Analyst view

Analysts rate MacroGenics Inc a buy (3 buy, 4 hold, 0 sell out of 7) with an average price target of $8.00.

Shareholding

Insiders
3.49%
Institutions
77.07%

Largest institutional holders

FundStake
Armistice Capital, LLC7.86%
BlackRock Inc7.35%
Vanguard Capital Management, LLC4.17%
Renaissance Technologies Corp4.13%
Acadian Asset Management LLC3.99%
Bank of America Corp3.91%
Two Sigma Investments LLC3.87%
Millennium Management LLC3.73%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MacroGenics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.